Market Place
Sourcing Support
All News #Library
Biotech
Palatin Unveils Melanocortin Therapy Data at ENDO 2025
06 Nov 2025 //
PR NEWSWIRE
Boehringer, Palatin to Develop Novel Retinal Disease Treatment
18 Aug 2025 //
GLOBENEWSWIRE
Palatin Reveals Preclinical Data for PL7737 in Obesity Model
15 Jul 2025 //
PR NEWSWIRE
Palatin Reports Symptom Relief in Dry Eye Phase 3 Trial
08 May 2025 //
PR NEWSWIRE
Palatin Technologies Announces Closing of Reduced Public Offering
08 May 2025 //
PR NEWSWIRE
Palatin Technologies Prices $23M Public Offering
07 May 2025 //
PR NEWSWIRE
Palatin Technologies Moves to OTC After NYSE Delisting Notice
07 May 2025 //
PR NEWSWIRE
Palatin Reports Positive Results From Phase 2 Obesity Study
17 Apr 2025 //
PR NEWSWIRE
Palatin`s Positive Ph 2b Data for Melanocortin in Diabetic Kidney Disease
10 Apr 2025 //
PR NEWSWIRE
Palatin Technologies Receives NYSE American Delisting Notice
10 Apr 2025 //
PR NEWSWIRE
Palatin`s Bremelanotide with Tirzepatide Meets Phase 2 Goal
31 Mar 2025 //
PR NEWSWIRE
Palatin Complete Ph 2 Obesity Study with Bremelanotide & Tirzepatide
06 Feb 2025 //
PR NEWSWIRE
Palatin Presents PL7737 Data for Obesity at ObesityWeek® 2024
04 Nov 2024 //
PR NEWSWIRE
Palatin Completes Enrollment in Bremelanotide Obesity Study
31 Oct 2024 //
PR NEWSWIRE
Palatin Presents Inflammatory Healing Data At Peptide Symposium
24 Oct 2024 //
PR NEWSWIRE
Palatin Presents Data On Selective Melanocortin 4 Receptor Agonists
23 Oct 2024 //
PR NEWSWIRE
Palatin Begins Phase 2 Study Of Bremelanotide With PDE5i For ED Treatment
20 Jun 2024 //
PR NEWSWIRE
Palatin Initiates Phase 2 Study Of Bremelanotide For Obesity
12 Jun 2024 //
PR NEWSWIRE
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Trial
05 Feb 2024 //
PR NEWSWIRE
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss
18 Oct 2023 //
PR NEWSWIRE
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643
07 Sep 2023 //
PR NEWSWIRE
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i
10 Aug 2023 //
PR NEWSWIRE
Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease
08 May 2023 //
PR NEWSWIRE
Frontiers in Immunology Publishes Study of Palatin`s Oral Formulation of PL8177
02 Mar 2023 //
PR NEWSWIRE
Palatin Initiates Enrollment in PII Bremelanotide BREAKOUT Study
19 Jan 2023 //
PR NEWSWIRE
Frontiers in Immunology Publishes Study of Palatin`s PL8177
10 Jan 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.